Psychoactive drug

Prodrugs: pills your body converts into an illicit drug can evade detection, but we don't know how big the problem is

Retrieved on: 
Monday, July 24, 2023

Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.

Key Points: 
  • Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.
  • Most illicit drugs work by interacting with specific brain cell receptors, stimulating or blocking the release of chemicals called neurotransmitters.
  • They last for a short time before being transformed into inactive or less active chemicals, which are then eliminated from the body, usually in urine.
  • For prodrugs, however, a small part of the molecule needs to be removed or substituted before it can act on those receptors.

Hard to detect

    • A major problem with prodrugs is they are difficult to detect.
    • Police forces need reference samples to compare the drug with, or advanced equipment to discover its molecular structure.
    • It also explains why many have only appeared in police reports in the past decade.
    • For biological samples (such as blood, urine or saliva), there is another difficulty.

Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023

Retrieved on: 
Tuesday, March 21, 2023

"Dr. Reid Robison continues to make key contributions to the study of new and innovative treatments for mental health disorders, such as PTSD, depression, and anxiety.

Key Points: 
  • "Dr. Reid Robison continues to make key contributions to the study of new and innovative treatments for mental health disorders, such as PTSD, depression, and anxiety.
  • "At Numinus we are focused on providing a holistic, integrated approach to healing, with all provided treatments being evidence-based.
  • We closely monitor advancing research to ensure Numinus is prepared to treat place patients look to when treatments become available."
  • Weekly group ketamine-assisted psychotherapy and integration provided immediate improvements in treating 10 frontline healthcare workers experiencing burnout, PTSD, depression, and anxiety.

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Retrieved on: 
Wednesday, January 25, 2023

Tel Aviv, Israel / Vancouver, Canada, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Professor Joseph Tam, D.M.D., Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating obesity, presented the latest results at Isranalytica 2023.

Key Points: 
  • The presentation, titled "The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its Metabolic Complications," included data from recently announced pre-clinical results demonstrating efficacy of Clearmind’s drug candidate MEAI for treating obesity and metabolic syndrome.
  • Isranalytica 2023, the Annual Meeting of the Israel Analytical Chemical Society, ranks as one of the world’s largest annual analytical chemistry conferences.
  • Professor Joseph Tam, D.M.D., Ph.D., heads the Obesity and Metabolism Laboratory, and he is an Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research.
  • Along with Dr. Saja Baraghithy, Ph.D., he led the pre-clinical trial as part of Clearmind’s robust collaboration with the Hebrew University and its technology transfer company Yissum .

New Study Shows That Aroma-Not THC-Drives the Cannabis Consumer Experience

Retrieved on: 
Wednesday, November 16, 2022

HILLSBORO, Ore., Nov. 16, 2022 /PRNewswire-PRWeb/ -- In a new study published in the journal Psychoactives, some of the most influential minds in the industry today are breaking down the current understanding of what makes a "quality" cannabis experience. And to do so, they've done something even more groundbreaking: they've asked the consumer.

Key Points: 
  • Groundbreaking new study led by True Terpenes Science Board members Dr. Ethan Russo and Jeremy Plumb shows correlation between cannabis aroma -- not THC -- and consumer enjoyment.
  • The study is revolutionary in its stated purpose: "to objectively identify features of cannabis that contribute to its appealing subjective effects."
  • In other words, to apply scientific methods to understanding what the consumer actually enjoys.
  • This study lays the groundwork for a redefinition of value, based on the enjoyment of the consumer, as reported by the consumer.

Journal of Psychoactive Drugs Publishes Peer Reviewed Ketamine Research Foundation Study on the Duration of the Presence of Ketamine in Breast Milk

Retrieved on: 
Monday, August 8, 2022

The research provides the first quantification of Ketamine and its major metabolites in human breast milk.

Key Points: 
  • The research provides the first quantification of Ketamine and its major metabolites in human breast milk.
  • The Ketamine Research Foundation believes this study will help open the door for further explorations of ketamine in the treatment of emotional disorders of the postpartum period, said Dr. Philip Wolfson, CEO of The Ketamine Research Foundation and a widely recognized leader in the development of Ketamine Assisted Psychotherapy.
  • The Ketamine Research Foundation is in the process of developing its protocol for postpartum depression and expects to launch it in the fall of 2022.
  • The Ketamine Research Foundation stands at the apex of Ketamine research and ketamine psychotherapy.

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

Retrieved on: 
Wednesday, February 23, 2022

The study shows the combinatorial approach used by GeneSight exceeds the effectiveness of single-gene testing at predicting sertraline metabolism in patients with major depressive disorder (MDD).

Key Points: 
  • The study shows the combinatorial approach used by GeneSight exceeds the effectiveness of single-gene testing at predicting sertraline metabolism in patients with major depressive disorder (MDD).
  • Using data (n=124) from the Genomics Used to Improve DEpression Decisions (GUIDED) randomized-controlled trial, the analysis evaluated the clinical validity of GeneSights combinatorial pharmacogenomic algorithm to predict sertraline blood levels.
  • Sertraline blood levels were compared between phenotypes based on: 1) the pharmacokinetic portion of the combinatorial pharmacogenomic algorithm, and 2) individual genes.
  • Psychiatry Research previously published two studies evaluating the combinatorial approach of the GeneSight test as compared to single-gene testing.

IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety

Retrieved on: 
Thursday, May 27, 2021

FRESNO, Calif., May 27, 2021 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, now offers pharmacogenomics testing for patients suffering from depression or anxiety.

Key Points: 
  • FRESNO, Calif., May 27, 2021 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, now offers pharmacogenomics testing for patients suffering from depression or anxiety.
  • GeneSight is a psychotropic test that analyzes how a person's genes impact how they may break down or respond to medications commonly prescribed to treat depression, anxiety, and other psychiatric conditions.
  • "Pharmacogenomics is a game-changing employee benefit," said Rich Adams, president and chief operating officer at IPM.
  • "With proper treatment, people who suffer from depression or anxiety can get better," said Alex Habibe, MD, IPM's medical director.

Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy

Retrieved on: 
Thursday, December 10, 2020

The Kelowna location will offer eight treatment rooms and will serve a very important role to Mind Cure beyond its therapeutic opportunities.

Key Points: 
  • The Kelowna location will offer eight treatment rooms and will serve a very important role to Mind Cure beyond its therapeutic opportunities.
  • Mind Cure announced earlier this week that it is initiating its translational research program, focused on psilocybin, ketamine and ibogaine.
  • The first two psychoactive compounds, psilocybin and ketamine, will be the first offered at the Health Center.
  • Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments.

Allied Corp. Obtains Approval to Sell From the Colombian Institute of Agriculture (ICA)

Retrieved on: 
Thursday, October 15, 2020

This approval enables Allied to now process and sell its Colombian non-psychoactive production and request a quota for the sale of its psychoactive production.

Key Points: 
  • This approval enables Allied to now process and sell its Colombian non-psychoactive production and request a quota for the sale of its psychoactive production.
  • This has been a year-long process that began with the registration of the ten (10) novel Allied strains with the national cultivar registry.
  • During this time, the strains were provided with propriety nutrients, handled with standard operating procedures and guided towards the plant flowering phase.
  • These lab results, batch records and procedural archives, were submitted to the Colombian Institute of Agriculture and a day-long presentation was provided by Allieds team.

Therapeutic Drug Monitoring Market worth $2.0 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, September 7, 2020

In 2019, immunoassays segment accounted for the largest market share, due to the increasing incidence of chronic and infectious diseases and technological innovation.

Key Points: 
  • In 2019, immunoassays segment accounted for the largest market share, due to the increasing incidence of chronic and infectious diseases and technological innovation.
  • On the basis of class of drug, the market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive agents, and other drugs.
  • Get 10% Customization on this Research Report:
    North America commanded the largest share of the therapeutic drug monitoring market in 2019.
  • On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.